What question did this study set out to answer?

To summarize recent developments in market access and health technology assessment.

February 25, 2026Open Access

Access in all areas? A round-up of developments in market access and health technology assessment: part 13

Key Points

To summarize recent developments in market access and health technology assessment.
Reviewed announcements from the US-UK Economic Prosperity Deal
Analyzed changes in NICE's cost-effectiveness thresholds
Evaluated US pharmaceutical pricing policies and models
NICE announced its first major cost-effectiveness threshold increase in over twenty years
The Inflation Reduction Act introduced a second cycle of drug price negotiations
Most-Favored-Nation pricing models like GENEROUS, GUARD, and GLOBE are now implemented.

Abstract

In this update we cover the US-UK Economic Prosperity Deal announced in December 2025, which includes NICE's first major cost-effectiveness threshold increase in over two decades. We also analyze the latest developments in US pharmaceutical pricing policy, including the second cycle of Inflation Reduction Act drug price negotiations and the implementation of the GENEROUS, GUARD and GLOBE Models for Most-Favored-Nation pricing.

Read Full Paperexternally

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Ramagopalan et al. (Mon,) studied this question.

synapsesocial.com/papers/699e911bf5123be5ed04e676 https://doi.org/https://doi.org/10.57264/cer-2026-0041

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Demander à l'IA

Bookmark

View Full Paper